The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $116.58

Today's change-2.36 -1.98%
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $116.58

Today's change-2.36 -1.98%
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd down (U.S.)$2.36

Taro Pharmaceutical Industries Ltd closed sharply lower Friday, dropping (U.S.)$2.36 or 1.98% to (U.S.)$116.58. Over the last five days, shares are unchanged, but have gained 10.74% over the last year to date. This security has underperformed the S&P 500 by 40.83% during the last year.

Key company metrics

  • Open(U.S.) $118.20
  • Previous close(U.S.) $118.94
  • High(U.S.) $118.49
  • Low(U.S.) $116.19
  • Bid / Ask-- / --
  • YTD % change+10.74%
  • Volume29,485
  • Average volume (10-day)128,306
  • Average volume (1-month)119,577
  • Average volume (3-month)175,166
  • 52-week range(U.S.) $92.28 to (U.S.) $152.30
  • Beta0.73
  • Trailing P/E9.97×
  • P/E 1 year forward10.60×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.69
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+51.59%

Based on its net profit margin of 51.59%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.57%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue220229234265
Total other revenue--------
Total revenue220229234265
Gross profit167177183224
Total cost of revenue53515141
Total operating expense91879183
Selling / general / administrative20212223
Research & development18151820
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income129142143182
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax161160140138
Income after tax140124110115
Income tax, total20363023
Net income140124110115
Total adjustments to net income--------
Net income before extra. items140124110115
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items140124110115
Inc. avail. to common incl. extra. items140124110115
Diluted net income140124110115
Dilution adjustment--------
Diluted weighted average shares41414243
Diluted EPS excluding extraordinary itemsvalue per share3.423.002.602.68
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.423.002.602.69